Business Wire

MD-TELEDYNE-FLIR

8.3.2022 13:03:05 CET | Business Wire | Press release

Share
As Drone Strikes Rise, Multi-Layered Approach is Crucial to Countering New and Emerging Threats

In a new whitepaper, Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), finds that a multi-layered approach, incorporating common architectures and information sharing, among other imperatives, is needed to address the threat to life and property posed by weaponized use of small Unmanned Aerial Systems (sUAS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308005265/en/

In January, non-state actors from Yemen utilized small unmanned aerial systems to launch deadly attacks in the United Arab Emirates that destroyed three refueling vehicles and damaged Abu Dhabi’s international airport. Other drone incidents in the Persian Gulf region include a 2019 strike on the world’s largest oil processing facility in Saudi Arabia.

The whitepaper, ‘The Big Problem with Small Drones (and How to Address It) ,’ examines how governments worldwide face a growing need for flexible, tailorable, and affordable Counter-sUAS (C-sUAS) solutions. It looks at current C-sUAS strategy, identifies key challenges, and outlines the critical capabilities governments should consider.

“There’s no ‘silver bullet’ when it comes to countering the huge risks presented by weaponized drones in the hands of bad actors,” said Dr. David Cullin, vice president and general manager of Unmanned and Integrated Solutions at Teledyne FLIR Defense. “What we’ve learned is that governments must address a host of challenges in concert to optimize their defense readiness in the face of UAS attacks.

“Nations around the globe are spending millions of dollars on commercially-built counter-drone solutions to address the immediate risks posed by these threats. But they need to approach the problem smartly, both from a technology and cost perspective. Our new whitepaper offers a number of insights from our team of experts,” Cullin adds.

Key findings include:

  • State and non-state actors are increasingly employing military- and consumer-grade drones to attack personnel, facilities and critical infrastructure
  • Counter-drone solutions must be cost effective, leveraging existing technologies through common electronic architectures and standard interfaces to ensure rapid integration of hardware and software upgrades
  • Solutions must be modular, interoperable and multi-domain; easily transportable; and capable of detecting drone swarms
  • Modern C-sUAS must be able to operate in contested environments where the ability to find, track, target, engage and assess threats can be disrupted by peer adversaries’ electronic warfare capabilities
  • Current and future C-sUAS systems must be flexible in employing both hard kill (kinetic) and soft kill (non-kinetic) countermeasures, allowing them to operate anywhere in the world in accordance with local restrictions and rules of engagement.

As the paper sums up, ‘The threat of small drones in the wrong hands promises to remain significant for government and military decision-makers as they seek to defend forward-deployed units, airports, power grids, and other critical infrastructure. Only the deployment of mature, flexible, and cost effective C-sUAS solutions will provide the required levels in protection as this threat continues to evolve at pace.”

About Teledyne FLIR

Teledyne FLIR, a Teledyne Technologies company, is a world leader in intelligent sensing, unmanned systems, and integrated solutions for defense and industrial markets, with roughly 4,000 employees worldwide. Founded in 1978, the company develops a wide range of advanced technologies to help professionals make better, faster decisions that save lives and livelihoods. To learn more, visit teledyneflir.com or follow @flir. #AnyThreatAnywhere

About Teledyne Technologies

Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye